Blog

 

Standard dosing works for most people because it was designed for most people. The problem is that "most people" is a statistical middle, and a sizable portion of patients sit outside it. They metabolize medications faster or slower than the guidelines assume. Those patients aren't harder to treat. They just need prescribing that starts with more information. 

 

Pharmacogenetic testing is where that information comes from. Rather than asking only which drug fits the diagnosis, it asks whether your body will process that drug the way the dose assumes. For a lot of patients, that turns out to be the most important question. 

 

Why Two People React So Differently to the Same Drug 

Two patients walk in with the same diagnosis. They leave with the same prescription, the same dose, and the same instructions. One improves. The other doesn't or get side effects the first person never had. The prescriber adjusts, tries something else, keeps notes. What rarely gets asked is whether the problem was the drug at all. 

 

When you take a medication, your liver enzymes break it down, activate it, or clear it from your system. How fast that happens determines whether the drug reaches the concentration it was designed for. If your body clears it too quickly, you never get there. If it clears too slowly, you overshoot. The dose on the label was calculated for the middle of the population, and a meaningful number of patients don't sit there. 

 

One enzyme family, CYP450, handles a large share of that clearing work. One member of that family, CYP2D6, covers 25% of commonly prescribed medications, including antidepressants, beta-blockers, and antipsychotics. That figure is well-established in the pharmacogenomics literature. A single gene variant can change how a patient responds to a quarter of what a GP might prescribe. 

 

People with variants in CYP2D6 fall into four groups: poor metabolizers, intermediate metabolizers, normal metabolizers, and ultra-rapid metabolizers. A patient taking codeine who is a poor metabolizer produces almost none of the morphine it converts into for pain relief. An ultra-rapid metabolizer produces more than intended. Neither patient knows this until something goes wrong. 

 

The Real Cost of Trial-and-Error Prescribing 

The standard prescribing process starts with a reasonable drug choice, a standard dose, and monitoring to see what happens. Adjustments get made if the response is poor. This works well when the first choice fits the patient. When it doesn't, the process stretches. 

 

A patient going through their third antidepressant in a year starts wondering what's wrong with them. That question is always aimed at the wrong thing. A study found that genetic testing for CYP2C19 and CYP2D6 variants could influence treatment decisions for up to a third of Canadians receiving medication for depression.  

 

Those patients weren't treatment resistant. They were metabolizing the drugs in a way the prescribing process never checked for. One of those problems has a straightforward solution that doesn't involve trying a fourth medication.

 

Pharmacogenetic testing doesn't replace a doctor's judgment or a pharmacist's clinical knowledge. It gives them better information before the first prescription is written. A patient whose CYP2C19 variant makes standard antidepressant doses ineffective finds that out before six months of treatment that was never going to work.  

 

DNA medication prescriptions match the drug to how a patient's body processes it, not how the average patient in a clinical trial did. The trial doesn't have to come first. 

 

 

Where Genetics Changes the Picture Most 

Not every prescription needs a genetic workup. Where genetics makes the biggest difference is when someone has already had an unexpected response to a medication, when the drug class varies widely between individuals, or when a patient is managing several medications at once. 

 

Psychiatric medications are where this pattern shows up most consistently. Patients taking antidepressants and antipsychotics rely heavily on CYP2D6 and CYP2C19, and both genes show wide variation across the population.  

 

CAMH opened Canada's first pharmacogenetics research clinic for mental illness in 2008, specifically to understand how patients' genes influence their response to medications for depression, anxiety, and schizophrenia. The pattern the clinic kept seeing was patients labelled as difficult to treat who were metabolizing their medications differently than the standard dose assumed. 

 

Cardiovascular medications are where the stakes get higher. A patient starting warfarin (Coumadin) after a cardiac event gets a standard starting dose. A patient carrying certain CYP2C9 variants needs less to hit the target INR.  

 

Patients with these variants require lower doses and carry a greater risk of bleeding at standard doses, a finding supported by the CADTH review on warfarin pharmacogenomics. Without that genetic information, the early weeks of dosing involve adjusting without knowing why a patient is responding differently than expected. 

 

Clopidogrel (Plavix) presents a different version of the same problem. A patient takes it every day after a stent because it's supposed to prevent blood clots. But clopidogrel is a prodrug — the liver must convert it into its active form before it does anything useful. That conversion runs primarily through CYP2C19.  

 

A patient who metabolizes slowly through that enzyme gets extraordinarily little active compound from a standard dose. The Clinical Pharmacogenetics Implementation Consortium is direct: avoid clopidogrel in poor and intermediate metabolizers and use an alternative. 

 

Pain management runs into the same enzyme. A patient taking codeine relies on CYP2D6 to convert it to morphine. Someone who metabolizes poorly gets inadequate pain relief. An ultra-rapid metabolizer gets more morphine than the dose was designed to produce. Health Canada has restricted codeine-containing products to adults only, citing the unpredictable metabolism of codeine through CYP2D6 as a key safety concern. 

 

What Actually Happens When You Get Tested 

Getting tested is simpler than most patients expect. A pharmacist swabs the inside of your cheek, the sample goes to a lab, and the lab identifies variants across a panel of relevant genes. The results come back as a structured report mapping your genetic findings to specific drug classes and medications, with guidance on how your body is likely to handle each one. 

 

Cook's offers pharmacogenetic testing in Kitchener, Waterloo, Guelph, and across the region through Inagene. Inagene is a Canadian company with its lab in Toronto. The report is structured for clinical use. A pharmacist goes through it with you, connects the findings to your current medications, and identifies anything worth raising with your prescriber. 

 

The test doesn't predict whether a medication will work in every sense. Your health status, other medications, lifestyle, and the nature of your condition all play a role alongside genetics. What the report does is identify metabolic risk and flag medications likely to underperform or cause unexpected effects in your specific case. 

 

When You're Managing More Than One Medication 

Patients managing several medications run into a compounding version of the same problem. When two medications both rely on the same enzyme, one can slow down the clearance of the other and push levels higher than either dose was designed to produce. This is drug-gene interaction, and it's hard to predict without knowing a patient's baseline genetic profile. 

 

A patient stable on two medications for a year adds a third. Suddenly the first one behaves differently — not because anything changed about it, but because the new drug is competing for the same enzyme pathway. This pattern comes up regularly in consultations. The interaction is real, predictable with the right information, and much easier to catch before it affects the patient than after. 

 

 

How to Know if Testing Makes Sense for You 

Genetic testing isn't the right move for every patient. For straightforward medications that don't show much metabolic variability, the information it adds is limited. It makes the most sense when a patient has already tried two or more medications for the same condition without the expected results.  

 

It also makes sense when managing several medications and a recent addition seems to have changed how the others are performing, or when starting a medication like warfarin where getting the starting dose right matters. 

 

Genetic testing doesn't replace a medication review. It makes a review more useful, and at Cook's, those two things happen together. A pharmacist works from both a complete medication list and a genetic report, catching things that neither piece of information would reveal on its own. 

 

How Cook's Approaches Testing 

For patients already in that process, the conversation about pharmacogenetic testing tends to come up naturally. Someone brings in their medications, a pharmacist notices two that may be competing for the same enzyme pathway, and the question of why shifts from the condition to the chemistry.  

 

Sometimes that leads to a dose adjustment or a timing change. Sometimes it points toward examining the genetic profile before the next prescription gets written. Personalized medication decisions look different when you have that picture from the start. 

 

All Cook's locations across the Kitchener-Waterloo and Guelph region offer testing through Inagene. If you've been through more than one medication trial without the results you were hoping for, or you're managing a complex regimen and want a clearer picture of what's driving it, book a consultation with a pharmacist.